ETF Holdings Breakdown of NRIX

Stock NameNurix Therapeutics Inc
TickerNRIX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS67080M1036

News associated with NRIX

First Trust Advisors LP Acquires New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
First Trust Advisors LP bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 135,903 shares of the company’s stock, valued at approximately $2,560,000. First Trust Advisors LP owned approximately […] - 2025-05-05 09:24:57
Invesco Ltd. Sells 361,360 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Invesco Ltd. lessened its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 87.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,980 shares of the company’s stock after selling 361,360 shares during the quarter. Invesco Ltd.’s holdings […] - 2025-05-02 08:06:53
Norges Bank Purchases Shares of 318,800 Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Norges Bank acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm acquired 318,800 shares of the company’s stock, valued at approximately $6,006,000. Other institutional investors also recently bought and sold shares of the company. NEOS Investment Management LLC purchased a new stake in […] - 2025-04-10 08:34:49
Vanguard Group Inc. Has $81.87 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Vanguard Group Inc. boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.3% during the 4th quarter, HoldingsChannel reports. The fund owned 4,345,266 shares of the company’s stock after acquiring an additional 333,452 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Nurix Therapeutics worth $81,865,000 as of its most […] - 2025-04-10 07:44:59
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12-month price […] - 2025-03-27 06:38:49
Bank of New York Mellon Corp Purchases 15,639 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Bank of New York Mellon Corp lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 190,905 shares of the company’s stock after buying an additional 15,639 shares during the […] - 2025-03-20 08:28:53
US Bancorp DE Has $27,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
US Bancorp DE raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 144.7% in the 4th quarter, HoldingsChannel reports. The fund owned 1,424 shares of the company’s stock after acquiring an additional 842 shares during the period. US Bancorp DE’s holdings in Nurix Therapeutics were worth $27,000 at the end of the […] - 2025-03-20 08:28:53
Leerink Partners Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX)
Leerink Partners began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report published on Monday morning, MarketBeat Ratings reports. The firm issued a market perform rating and a $16.00 price target on the stock. Several other equities analysts also recently commented on the company. HC Wainwright increased their price target on […] - 2025-03-18 06:30:53
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $31.81
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price objective […] - 2025-03-05 06:53:07
Rhumbline Advisers Acquires 12,315 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Rhumbline Advisers raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 13.5% during the fourth quarter, Holdings Channel reports. The firm owned 103,233 shares of the company’s stock after buying an additional 12,315 shares during the quarter. Rhumbline Advisers’ holdings in Nurix Therapeutics were worth $1,945,000 at the end of […] - 2025-03-04 08:10:55
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target indicates a potential downside of 8.55% from […] - 2025-02-05 06:44:53

NRIX institutional holdings

The following institutional investment holdings of NRIX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-13 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 38,221 0.5%USD 371,890 -4.1%
2025-05-13 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 21,121USD 205,507
2025-05-13 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 35,547USD 345,872
2025-05-13 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 35,547USD 345,872
2025-05-13 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 392USD 3,814
Total =130,828 USD 1,272,955
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.